1. Ausems MGEM, Verbiest J, Hermans MMP, et al. Frequency of glycogen storage disease type II in the Nethelands: Implications for diagnosis and genetic counseling. Eur JHum Genet. 1999;7:713-716.
2.
2. Raben N, Nichols RC, Boerkoel C, et al. Genetic defects in patients with glycogenosis type II. Muscle Nerve1995; (suppl 3):S70-S74.
3.
3. Lee C-C, Chen C-Y, Chou T-Y, et al. Cerebral MR manifestations of Pompe's disease in an infant. AJNIR1996;17:321-322.
4.
4. Reuser AJJ, Kroos MA, Hermans MMP, et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve. 1995; (suppl 3):S61-S69.
5.
5. Bodamer OAF, Leonard JV, Halliday D. Dietary treatment in late onset acid maltase deficiency. Eur J Pediatr. 1997;156(suppl 1):S39-S42.
6.
6. Kikuchi T, Wen Yang H, Pennybacker M, et al. Clinical and metabolic corection of Pompe's disease by enzyme therapy in acid maltase-deficient quail.J Clin Invest. 1998;1101:827-833.
7.
7. Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glcosidase from rabbit milk in Pompe patients [letter]. Lancet. 2000;356:397-398.
8.
8. Poenaru L. Approach to gene therapy of glycogenosis type II. Mol Genet Metab. 2000;70:163-169.
